Skip to main content
OpenTrials
Completed

NCT Number: NCT04540406

NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients

This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat early-stage suspected or confirmed symptomatic COVID-19 patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of South Florida Morsani College of Medicine

Tampa, Florida, 33612, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 18 to 79 (inclusive)
  • Have mild to moderate COVID-19-like symptoms based on the symptom list from CDC (updated May 13, 2020) and the severity categorization from FDA [18]:

a) Mild COVID-19

  • Fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea
  • No clinical signs indicative of moderate, severe, or critical illness severity

b) Moderate COVID-19

  • Symptoms of moderate illness with COVID-19 could include any symptom of mild illness or shortness of breath with exertion
  • Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate ≥ 20 breaths/min, oxygen saturation level > 93% on room air at sea level, heart rate ≥ 90 beats/min
  • No clinical signs indicative of severe or critical illness severity
  • Directed to home isolation by study physician
  • Confirm study enrollment within 7 days of symptom onset
  • Practice acceptable contraception, i.e., continue with current methods if participants are already practicing contraception, otherwise participants must agree to practicing contraception with a barrier method (male or female condom) or abstinence, from Day 1 to Day 35 or 7 days after the last dose of NBT-NM108 if they do not complete the 28-day intervention.
  • Have access to a smartphone, tablet, computer, or other qualifying internet-enabled device and daily internet access
  • Understand and be able to follow written and oral instructions in English
  • Provide informed consent

Exclusion criteria

  • Have tested positive for COVID-19 and recovered
  • Receiving vancomycin monotherapy or oral broad-spectrum antibiotics
  • Inability to receive oral fluids
  • Self-reported allergy or intolerance to any ingredients in NBT-NM108
  • Surgery involving the intestinal lumen within the last 30 days
  • Documented diagnosis of celiac disease, inflammatory bowel disease or irritable bowel syndrome
  • Pregnancy or breastfeeding
  • Bariatric surgery
  • Immunocompromised, e.g., cancer treatment, bone marrow/organ transplant, immune deficiency, poorly controlled HIV/AIDS, prolonged use of steroids or other immunosuppressant medications

Treatment and study plan

NBT-NM108

Drug

Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.

Usual Care Only

Other

Control group will also follow the same schedule except they will drink the same volume of water without NBT-NM108.

Primary outcomes

  1. Amplicon Sequence Variants (ASVs) That Are Significantly Correlated With Variation in the Microbiome Data Between NBT-NM108 Group and Usual Care Only Group From Day 0 to 28

    Time frame: Day 0-28

    Amplicon Sequence Variants (ASVs) significantly correlated with the first principal coordinate (PC1) from the covariate-adjusted Principal Coordinates Analysis (aPCoA) were identified, each having an average relative abundance greater than 0.001%. These ASVs represent specific microbial features whose relative abundance was most strongly associated with the primary axis of variation in the microbiome data, after adjusting for covariates. It was hypothesized that PC1 might reflect the direction of microbiome changes induced by the intervention, given its association with shifts observed in participants' microbiome compositions before and after the intervention. The unit of measure used here is the relative abundance percentage of each ASV in the stool sample.

Secondary outcomes

  1. Number of Participants That Were Hospitalized or Died From COVID19

    Time frame: At days 0, 14, 28, and 56

    Hospitalization or death

  2. Proportion of Participants Who Are "Alive and Not Admitted to the Hospital"

    Time frame: At days 0, 14, 28, and 56

    (not specified)

  3. Number of Participants Who Visited the Emergency Room From COVID-19

    Time frame: At days 0, 14, 28, and 56

  4. Proportion of Participants Who Have Complete Resolution of Objective Symptoms

    Time frame: At days 28 and 56

    All vitals signs are within normal range for at least 24h, including body temperature 36.4-37.5C (97.7-99.5F), pulse rate <90/min, respiratory rate 12-16/min, and oxygen saturation level at 95-100%.

  5. Proportion of Participants Who Have Complete Resolution of Subjective Symptoms

    Time frame: At days 28 and 56

    Absence of all COVID-19-like symptoms listed by CDC (updated May 13, 2020) for at least 48h, including the presence of chills or "feeling feverish" , cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea

  6. Proportion of Participants Who Have Complete Resolution of Subjective Symptoms Except Fatigue and Cough

    Time frame: At days 28 and 56

    Proportion of participants who have complete resolution of subjective symptoms except fatigue and cough, i.e. absence of all COVID-19-like symptoms listed by CDC (updated May 13, 2020) for at least 48 h, including the presence of chills or "feeling feverish", cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea

  7. Illness Severity Based on the Categorization From FDA and World Health Organization COVID-19 Guidance Document

    Time frame: Day 0

    Proportion of participants who meet each COVID-19 category in both mild, moderate, and severe categories

  8. Oral Body Temperature (F)

    Time frame: At days 0, 14, 28, and 56

  9. Oxygen Saturation SpO2 Level

    Time frame: At days 0, 14, 28, and 56

  10. Pulse Rate Per Minute

    Time frame: At days 0, 14, 28, and 56

  11. Respiratory Rate Per Minute

    Time frame: At days 0, 14, 28, and 56

  12. Fasting Blood Glucose

    Time frame: At days 0 and 28

Sponsors and collaborators

Lead sponsor

Notitia Biotechnologies Company

Industry

Collaborators

  • Rutgers University
  • University of South Florida

Registry information

Official study title

Modulation of Gut Microbiota With NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients

Acronym: COVGUT20

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Sep 7, 2020
Registry last updated
Oct 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.